PMID- 30284992
OWN - NLM
STAT- MEDLINE
DCOM- 20190125
LR  - 20221207
IS  - 0975-4466 (Electronic)
IS  - 0256-4947 (Print)
IS  - 0256-4947 (Linking)
VI  - 38
IP  - 5
DP  - 2018 Sep-Oct
TI  - Dapoxetine for the treatment of premature ejaculation: a meta-analysis of 
      randomized controlled trials with trial sequential analysis.
PG  - 366-375
LID - 10.5144/0256-4947.2018.366 [doi]
AB  - BACKGROUND: The safety and efficacy of dapoxetine for the treatment of premature 
      ejaculation (PE) is still controversial. Thus, we decided to conduct a 
      meta-analysis using trial sequential analysis (TSA) to determine the sufficiency 
      of conclusions. OBJECTIVE: Evaluate the efficacy and safety of dapoxetine in the 
      treatment of patients with PE and assess the reliability of the findings. DESIGN: 
      Meta-analysis of randomized controlled trials (RCTs). METHODS: Electronic 
      databases including PUBMED, EMBASE, Cochrane Library, CNKI and Wanfang data were 
      reviewed up to July 2017. RCTs evaluating the efficacy of dapoxetine in patients 
      with PE and reporting intravaginal ejaculatory latency time (IELT), patient 
      global impression of change (PGIC) and/or adverse events (AEs) were included. 
      MAIN OUTCOME MEASURES: Mean differences between trials in efficacy for IELT, and 
      risk ratios for PGIC and treatment-emergent AEs. SAMPLE: 8 RCTs. RESULTS: For 
      IELT and PGIC, significant effects were found for all doses of dapoxetine versus 
      placebo, and similar results were obtained in subgroups of the 30-mg dose versus 
      60-mg dose. There were also statistically different dose-related effects on AEs. 
      Trial sequential analysis showed that the result of our meta-analysis was 
      confirmed and further trials are unnecessary. CONCLUSIONS: The evidence suggests 
      that dapoxetine may be a safe and effective drug for patients with PE. 
      REGISTRATION: Not registered, no published protocol. CONFLICT OF INTEREST: No 
      relationship with manufacturer of drug.
FAU - Li, Jing
AU  - Li J
AD  - Dr. Jing Li, Department of Urology,, Xinxiang Central Hospital,, Xinxiang 453000, 
      China, T: +8613462286403, hnxx.lijing029@163.com, ORCID: http:// 
      orcid.org/0000-0003-3030-354X.
FAU - Liu, Dezhi
AU  - Liu D
FAU - Wu, Jinfeng
AU  - Wu J
FAU - Fan, Xiaoyong
AU  - Fan X
FAU - Dong, Qianqian
AU  - Dong Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Saudi Arabia
TA  - Ann Saudi Med
JT  - Annals of Saudi medicine
JID - 8507355
RN  - 0 (Benzylamines)
RN  - 0 (Naphthalenes)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - GB2433A4M3 (dapoxetine)
SB  - IM
MH  - Benzylamines/adverse effects/*therapeutic use
MH  - Ejaculation/drug effects
MH  - Humans
MH  - Male
MH  - Naphthalenes/adverse effects/*therapeutic use
MH  - Premature Ejaculation/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use
MH  - Time Factors
PMC - PMC6180218
COIS- CONFLICT OF INTEREST: No relationship with manufacturer of drug.
EDAT- 2018/10/05 06:00
MHDA- 2019/01/27 06:00
PMCR- 2018/09/01
CRDT- 2018/10/05 06:00
PHST- 2018/10/05 06:00 [entrez]
PHST- 2018/10/05 06:00 [pubmed]
PHST- 2019/01/27 06:00 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - asm-5-366 [pii]
AID - 10.5144/0256-4947.2018.366 [doi]
PST - ppublish
SO  - Ann Saudi Med. 2018 Sep-Oct;38(5):366-375. doi: 10.5144/0256-4947.2018.366.